Citations

Clear

199 citation(s) found for "Lu, Cathy".

Altered resting-state network connectivity in stroke patients with and without apraxia of speech (S49.002)
New, Anneliese , Kirrie, Ballard, Parkinson, Amy, McNeil, Malcolm, Price, Cathy J. , Robin, Donald A., Duffy, Joseph R. , Piguet, Olivier , Hornberger, Michael , Eickhoff, Simon Bodo

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.s49.002 Get It

Muc1 Modulates the Beta‐Catenin Protective Pathway During Ischemia‐Reperfusion Injury
Kinlough, Carol L., Poland, Paul A., Gendler, Sandra , Madsen, Cathy S., Singh, Sucha , Bastacky, Sheldon , Hughey, Rebecca P. , Al‐bataineh, Mohammad M. , Pastor‐Soler, Núria M. , Sutton, Timothy A. , Mang, Henry Elmer , Monga, Satdarshan P.

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.1217.5 Get It

The HIF‐1 and β‐catenin protective pathways represent the two most significant cellular responses that are activated in response to acute kidney injury. We previously reported that murine Mucin 1 (Muc1) protects kidney function and morphology in a mouse model of ischemia‐reperfusion injury (IRI) by stabilizing HIF‐1α, enhancing HIF‐1 downstream signaling and thereby preventing metabolic stress (Pastor‐Soler et al. 2015 Am. J. Physiol. Renal Physiol. 308, F1452‐F1462). We asked if Muc1 regulates the β‐catenin protective pathway during IRI as published data indicate that (i) β‐catenin is found in co‐immunoprecipitates with human MUC1 in extracts of both cultured cells and tissues, (ii) β‐catenin nuclear targeting is MUC1‐dependent in cultured human cells, and (iii) MUC1 prevents β‐catenin phosphorylation by glycogen synthase kinase 3β (GSK3b) and thereby β‐catenin degradation. Using our same mouse model of IRI, and by using immunohistochemistry and immunoblotting of kidney tissue, we found that levels of active GSK3β were significantly lower in kidneys of control mice compared to Muc1 KO mice. Consequently, β‐catenin was significantly increased at 24 and 72 h recovery and appeared in the nuclear fraction at 72 h in control mouse kidneys. Both β‐catenin induction and nuclear targeting were absent in Muc1 KO mice. In accord with these data, we also found downstream induction of β‐catenin pro‐survival factors (activated Akt, survivin, transcription factor TCF4 and its downstream target cyclin D1) and repression of pro‐apoptotic factors (p53, active Bax and cleaved caspase 3) in control mouse kidneys that were absent or aberrant in kidneys of Muc1 KO mice. Altogether, the data clearly indicate that Muc1 protection during AKI proceeds by enhancing both the HIF‐1 and β‐catenin protective pathways. Support or Funding Information This work was supported by National Institutes of Health (NIH) Grants DK‐099345 (to T. A. Sutton), DK‐084184 (to N. M. Pastor‐Soler), CA‐64389 (to S. J. Gendler), DK‐62277, DK‐100287, and DK‐095498 (to S. P. Monga), DK‐097889 (to M. M. Al‐bataineh), DK107632, DK‐079307 (Pilot Project) and Samuel and Emma Winters Foundation grant (to R. P. Hughey), and P30‐DK079307 (to the Microscopy Core N. M. Pastor‐Soler and S. Bastacky).
Ein globaler Consensus zu Definitionen, Diagnostik und Behandlungsmanagement des fibrostenotischen Morbus Crohn des terminalen Ileums
Baker, Mark E. , Bemelman, Willem A. , D’Haens, Geert , D’Hoore, A., Feakins, Roger , Fleshner, Phillip , Ha, Christina , Lyu, R., Mao, Ren , Sandborn, William J. , Ng, S, Silverberg, Mark S. , Bruining, David H. , Feagan, Brian G. , Bettenworth, Dominik , Fletcher, Joel G. , Jairath, Vipul , Lu, Cathy , Dignass, Axel , Dotan, Iris , Henderson, G., Panés, Julián , Rogler, Gerhard , Rimola, Jordi , Siegmund, Britta , Taylor, Stuart A. , Verstockt, Bram , Gordon, Ilyssa O. , Rieder, F.

Mayo Clinic

Zeitschrift für Gastroenterologie | October 26, 2023 | Volume: 61 | Issue: 08 | Pages: e421-e422

10.1055/s-0043-1771750 Get It

The Future Ain’t What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations
Patel, Robin , Hamasaki, Toshimitsu , Howard‐Anderson, Jessica , Kinamon, Tori, King, H. A. , Cross, H. R. , Chambers, Henry F. , Fowler, Vance G. , Boucher, Helen W., Group, for the Antibacterial Resistance Leadership, Schooley, Robert T. , Banerjee, Ritu , Souli, Maria , Sund, Zoë, Evans, Beth , Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Schwager, Nyssa, Wickward, Cathy, Geres, Holly, Dai, Weixiao , He, Yijie, Doernberg, Sarah B. , Satlin, Michael J. , Rouphael, Nadine , Baum, Keri, Raza, Praneeta , Komarow, Lauren , Hopkins, D. E., Zhang, Shanshan , Patel, Robin , Evans, Scott R , Evans, Scott , King, Heather A, Collyar, Deborah , Cross, Heather R, Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Tamma, Pranita D. , Evans, Beth, Cunningham, Scott A. , Tillekeratne, L. Gayani , Dodd, Andrew, Hopkins, Deborah, Li, Yixuan , Tsalik, Ephraim L. , Holland, Thomas L

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S321-S330

10.1093/cid/ciad538 | PMID 37843122 Get It

Abstract Clinical research networks conduct important studies that would not otherwise be performed by other entities. In the case of the Antibacterial Resistance Leadership Group (ARLG), such studies include diagnostic studies using master protocols, controlled phage intervention trials, and studies that evaluate treatment strategies or dynamic interventions, such as sequences of empiric and definitive therapies. However, the value of a clinical research network lies not only in the results from these important studies but in the creation of new approaches derived from collaborative thinking, carefully examining and defining the most important research questions for clinical practice, recognizing and addressing common but suboptimal approaches, and anticipating that the standard approaches of today may be insufficient for tomorrow. This results in the development and implementation of new methodologies and tools for the design, conduct, analyses, and reporting of research studies. These new methodologies directly impact the studies conducted within the network and have a broad and long-lasting impact on the field, enhancing the scientific value and efficiency of generations of research studies. This article describes innovations from the ARLG in diagnostic studies, observational studies, and clinical trials evaluating interventions for the prevention and treatment of antibiotic-resistant bacterial infections.
The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions
Chambers, Henry F. , Cross, H. R. , Souli, Maria , Patel, Robin , Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Deckard, Nancie , Schuler, Carl, Bunn, Ivra, Zaharoff, Smitha, Sharma, Shrabani, Wickward, Cathy, Waller, Jason, Wilson, Holly, Baum, Keri, Komarow, Lauren , Evans, Beth , Hopkins, D. E., Ge, Lizhao , Giri, Abhigya, Dai, Weixiao , Diao, Guoqing , Fidler, Tamara, Shao, Wanying, Schwager, Nyssa, Mau, Donald, Satlin, Michael J. , Schooley, Robert T. , Sund, Zoë, Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Doernberg, Sarah B. , Raza, Praneeta , Zeng, Lijuan , Banerjee, Ritu , Abbenante, Erin, Mocka, Elizabeth, King, H. A. , Kinamon, Tori, Boucher, Helen W., Geres, Holly, He, Yijie, Mehigan, Maureen, Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Fowler, Vance G. , Patel, Robin , Evans, Scott R , Cross, Heather R, Evans, Scott , Group, for the Antibacterial Resistance Leadership, Lodise, Thomas P. , Schuler, Carl, Holland, Thomas L , Turner, Nicholas , Wilson, Holly, van Duin, David , Wang, Minggui, Evans, Beth, Hopkins, Deborah, Bonomo, Robert A. , Li, Yixuan , Tamma, Pranita D. , Hamasaki, Toshimitsu , Cunningham, Scott A. , Dodd, Andrew, Tsalik, Ephraim L. , Tillekeratne, L. Gayani , King, Heather, Kinamon, Tori, Howard‐Anderson, Jessica , Nayak, Seema , Samuel, Tamika

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S279-S287

10.1093/cid/ciad475 | PMID 37843121 Get It

AbstractIn this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research.
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group
Satlin, Michael J. , Tyne, Daria Van , Rouphael, Nadine , Fowler, Vance G. , Hamasaki, Toshimitsu , Patel, Robin , Komarow, Lauren , Baum, Keri, Souli, Maria , Schwager, Nyssa, Doi, Yohei , Group, for the Antibacterial Resistance Leadership, Schooley, Robert T., Evans, Beth , Hopkins, D. E., Cathcart, F, Mocka, Elizabeth, Schuler, Carl, Sund, Zoë, Zaharoff, Smitha, Wickward, Cathy, Estes, Leslie, Mau, Donald, Booth, Grant, Abbenante, Erin, Bhojani, Minal, Zahir, Hirra, Ge, Lizhao , Giri, Abhigya, Dai, Weixiao , Diao, Guoqing , Fidler, Tamara, Shao, Wanying, Li, Yixuan , Zeng, Lijuan , Zhang, Shanshan , Greenwood‐Quaintance, Kerryl E. , Malan, Suzannah Schmidt, Parmar, Krupa , Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Doi, Yohei , Patel, Robin , Van Tyne, Daria , Evans, Scott R , van Duin, David , Tamma, Pranita D. , Lodise, Thomas P. , Rodvold, Keith A. , Evans, Scott , Fowler, Vance G. , Bonomo, Robert A. , Group, for the Antibacterial Resistance Leadership, Wang, Minggui, Wenzler, Eric , Evans, Beth, Hopkins, Deborah, Cathcart, Felecia, Schuler, Carl, Cunningham, Scott A. , Samuel, Tamika, Nayak, Seema

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S305-S313

10.1093/cid/ciad547 | PMID 37843118 Get It

Abstract Addressing the treatment and prevention of antibacterial-resistant gram-negative bacterial infections is a priority area of the Antibacterial Resistance Leadership Group (ARLG). The ARLG has conducted a series of observational studies to define the clinical and molecular global epidemiology of carbapenem-resistant and ceftriaxone-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii, with the goal of optimizing the design and execution of interventional studies. One ongoing ARLG study aims to better understand the impact of fluoroquinolone-resistant gram-negative gut bacteria in neutropenic patients, which threatens to undermine the effectiveness of fluoroquinolone prophylaxis in these vulnerable patients. The ARLG has conducted pharmacokinetic studies to inform the optimal dosing of antibiotics that are important in the treatment of drug-resistant gram-negative bacteria, including oral fosfomycin, intravenous minocycline, and a combination of intravenous ceftazidime-avibactam and aztreonam. In addition, randomized clinical trials have assessed the safety and efficacy of step-down oral fosfomycin for complicated urinary tract infections and single-dose intravenous phage therapy for adult patients with cystic fibrosis who are chronically colonized with P. aeruginosa in their respiratory tract. Thus, the focus of investigation in the ARLG has evolved from improving understanding of drug-resistant gram-negative bacterial infections to positively affecting clinical care for affected patients through a combination of interventional pharmacokinetic and clinical studies, a focus that will be maintained moving forward.
Priorities and Progress in Diagnostic Research by the Antibacterial Resistance Leadership Group
Hanson, Kimberly E. , Banerjee, Ritu , Doernberg, Sarah B. , Komarow, Lauren , Satlin, Michael J. , Schwager, Nyssa, Simner, Patricia J. , Patel, Robin , Group, for the Antibacterial Resistance Leadership, Abbenante, Erin, Baum, Keri, Souli, Maria , Mocka, Elizabeth, Hopkins, D. E., Giri, Abhigya, Zeng, Lijuan , Greenwood‐Quaintance, Kerryl E. , Booth, Grant, Waller, Jason, Raza, Praneeta , Sund, Zoë, Wickward, Cathy, Dai, Weixiao , Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Patel, Robin , Evans, Scott R , Hanson, Kimberly , Evans, Scott , Tillekeratne, L. Gayani , Group, for the Antibacterial Resistance Leadership, Tsalik, Ephraim L. , Hopkins, Deborah, Dodd, Andrew, Li, Yixuan , Hamasaki, Toshimitsu , Samuel, Tamika

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S314-S320

10.1093/cid/ciad541 | PMID 37843119 Get It

Abstract The advancement of infectious disease diagnostics, along with studies devoted to infections caused by gram-negative and gram-positive bacteria, is a top scientific priority of the Antibacterial Resistance Leadership Group (ARLG). Diagnostic tests for infectious diseases are rapidly evolving and improving. However, the availability of rapid tests designed to determine antibacterial resistance or susceptibility directly in clinical specimens remains limited, especially for gram-negative organisms. Additionally, the clinical impact of many new tests, including an understanding of how best to use them to inform optimal antibiotic prescribing, remains to be defined. This review summarizes the recent work of the ARLG toward addressing these unmet needs in the diagnostics field and describes future directions for clinical research aimed at curbing the threat of antibiotic-resistant bacterial infections.